Beijing Biostar to place 25,000,000 shares at HK$ 4 each for HK$ 100 million

• Beijing Biostar Pharmaceuticals entered a conditional subscription agreement on May 7, 2026 to issue 25,000,000 new shares at HK$ 4 per share in a private placement to Baheal Wellness Industry International Trading, a unit of Shenzhen-listed Qingdao Baheal Pharmaceutical.
• Gross proceeds set at HK$ 100 million, with funds earmarked mainly for ADC product and platform development, commercialization cooperation, new project intake, and working capital.
• Placement size equals about 6.86% of existing shares, or 6.42% on an enlarged basis, based on 364,588,000 shares outstanding.
• Baheal Wellness held 4,170,800 shares pre-deal; stake would rise to 29,170,800 shares, or about 7.49%, on completion.
• Completion hinges on shareholder approval, Hong Kong listing approval for new shares, and regulatory clearances including CSRC filings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beijing Biostar Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260507-12152397), on May 07, 2026, and is solely responsible for the information contained therein.